STUDY PERIOD
Start date: August 3, 2022
End date: October 13, 2023
STUDY INFORMATION
Indication: The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among participants who are in the subpopulation of participants who were not expected to receive standard-of-care COVID-19 Group A therapy (defined as monoclonal antibody [mAb] treatment or outpatient intravenous [IV] remdesivir).
Frequency of Visit:
Screening Visit: 1
In Person Visit: 11
STUDY CRITERIA
Age: 18 to 64 years old
Gender: Both
